1
|
Wu S, Li X. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. Bioengineered 2021; 12:1642-1662. [PMID: 33955826 PMCID: PMC8806326 DOI: 10.1080/21655979.2021.1922330] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 12/25/2022] Open
Abstract
This study aims to originate agenomic instability-derived risk index (GIRI) for prognostic analysis of clear cell renal cell carcinoma (ccRCC) and explore the mutation characteristics, immune characteristics, and immunotherapy response defined by GIRI. Differentially expressed genome instability-associated genes were obtained from the genomic unstable (GU) group and the genomic stable (GS) group. Rigorous screening conditions were assigned to the screening of hub genes, which were then used to generate the GIRI through multivariate Cox regression analysis. The selected samples were assigned to the high-risk group or the low-risk group based on the median GIRI. Possible reasons for the prognostic differences in risk subgroups were explored from the aspects of mutation profiles, immune profiles, immunomodulators, and biological pathway activities. The possibility of immunotherapy response was predicted by Tumor Immune Dysfunction and Exclusion analysis results. The prediction of drugs that might reverse the expression profiles of the risk subgroups was discovered through theonnectivity Map (CMap). High-risk populations manifested poor overall survival than low-risk populations and were characterized by elevated cumulative mutation counts and tumor mutation burden. Also, high-risk populations had higher immune scores, immunomodulator (PD-1, CTLA4, LAG3, and TIGIT) expression, and genomic instability-related pathway activities, and were more likely to reap benefits from immunotherapy. Besides, we predicted several drugs (PI3K inhibitor, ATPase inhibitor, and phenylalanyl tRNA synthetase inhibitor) targeting risk subgroups. The well established GIRI was an effective cancer biomarker for predicting ccRCC prognosis and provided apotential reference value for identifying immunotherapy response.
Collapse
Affiliation(s)
- Sha Wu
- Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, China
| | - Xiaoning Li
- Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, China
| |
Collapse
|
4
|
Muter J, Brighton PJ, Lucas ES, Lacey L, Shmygol A, Quenby S, Blanks AM, Brosens JJ. Progesterone-Dependent Induction of Phospholipase C-Related Catalytically Inactive Protein 1 (PRIP-1) in Decidualizing Human Endometrial Stromal Cells. Endocrinology 2016; 157:2883-93. [PMID: 27167772 PMCID: PMC4972893 DOI: 10.1210/en.2015-1914] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Decidualization denotes the transformation of endometrial stromal cells into specialized decidual cells. In pregnancy, decidual cells form a protective matrix around the implanting embryo, enabling coordinated trophoblast invasion and formation of a functional placenta. Continuous progesterone (P4) signaling renders decidual cells resistant to various environmental stressors, whereas withdrawal inevitably triggers tissue breakdown and menstruation or miscarriage. Here, we show that PLCL1, coding phospholipase C (PLC)-related catalytically inactive protein 1 (PRIP-1), is highly induced in response to P4 signaling in decidualizing human endometrial stromal cells (HESCs). Knockdown experiments in undifferentiated HESCs revealed that PRIP-1 maintains basal phosphoinositide 3-kinase/Protein kinase B activity, which in turn prevents illicit nuclear translocation of the transcription factor forkhead box protein O1 and induction of the apoptotic activator BIM. By contrast, loss of this scaffold protein did not compromise survival of decidual cells. PRIP-1 knockdown did also not interfere with the responsiveness of HESCs to deciduogenic cues, although the overall expression of differentiation markers, such as PRL, IGFBP1, and WNT4, was blunted. Finally, we show that PRIP-1 in decidual cells uncouples PLC activation from intracellular Ca(2+) release by attenuating inositol 1,4,5-trisphosphate signaling. In summary, PRIP-1 is a multifaceted P4-inducible scaffold protein that gates the activity of major signal transduction pathways in the endometrium. It prevents apoptosis of proliferating stromal cells and contributes to the relative autonomy of decidual cells by silencing PLC signaling downstream of Gq protein-coupled receptors.
Collapse
Affiliation(s)
- Joanne Muter
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Paul J Brighton
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Emma S Lucas
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Lauren Lacey
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Anatoly Shmygol
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Siobhan Quenby
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Andrew M Blanks
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| | - Jan J Brosens
- Division of Biomedical Sciences (J.M., P.J.B., E.S.L., L.L., A.S., S.Q., A.M.B., J.J.B.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and University Hospitals Coventry and Warwickshire National Health Service Trust (S.Q., J.J.B.), Coventry, CV2 2DX United Kingdom; and Tommy's National Miscarriage Research Centre (E.S.L., S.Q., J.J.B.), University Hospital Coventry and Warwickshire, Coventry, CV2 2DX United Kingdom
| |
Collapse
|
5
|
Yamawaki Y, Oue K, Shirawachi S, Asano S, Harada K, Kanematsu T. Phospholipase C-related catalytically inactive protein can regulate obesity, a state of peripheral inflammation. JAPANESE DENTAL SCIENCE REVIEW 2016; 53:18-24. [PMID: 28408965 PMCID: PMC5390332 DOI: 10.1016/j.jdsr.2016.06.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2016] [Revised: 05/23/2016] [Accepted: 06/06/2016] [Indexed: 11/28/2022] Open
Abstract
Obesity is defined as abnormal or excessive fat accumulation. Chronic inflammation in fat influences the development of obesity-related diseases. Many reports state that obesity increases the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, sleep apnea, and breast, prostate and colon cancers, leading to increased mortality. Obesity is also associated with chronic neuropathologic conditions such as depression and Alzheimer's disease. However, there is strong evidence that weight loss reduces these risks, by limiting blood pressure and improving levels of serum triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol. Prevention and control of obesity is complex, and requires a multifaceted approach. The elucidation of molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) aims at developing clinical treatments to control obesity. We recently reported a new regulatory mechanism in fat metabolism: a protein phosphatase binding protein, phospholipase C-related catalytically inactive protein (PRIP), regulates lipolysis in white adipocytes and heat production in brown adipocytes via phosphoregulation. Deficiency of PRIP in mice led to reduced fat accumulation and increased energy expenditure, resulting in a lean phenotype. Here, we evaluate PRIP as a new therapeutic target for the control of obesity.
Collapse
Affiliation(s)
- Yosuke Yamawaki
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - Kana Oue
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.,Department of Dental Anesthesiology, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - Satomi Shirawachi
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - Satoshi Asano
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - Kae Harada
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - Takashi Kanematsu
- Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| |
Collapse
|
6
|
Oue K, Zhang J, Harada-Hada K, Asano S, Yamawaki Y, Hayashiuchi M, Furusho H, Takata T, Irifune M, Hirata M, Kanematsu T. Phospholipase C-related Catalytically Inactive Protein Is a New Modulator of Thermogenesis Promoted by β-Adrenergic Receptors in Brown Adipocytes. J Biol Chem 2015; 291:4185-96. [PMID: 26706316 DOI: 10.1074/jbc.m115.705723] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Indexed: 11/06/2022] Open
Abstract
Phospholipase C-related catalytically inactive protein (PRIP) was first identified as an inositol 1,4,5-trisphosphate-binding protein, and was later found to be involved in a variety of cellular events, particularly those related to protein phosphatases. We previously reported that Prip knock-out (KO) mice exhibit a lean phenotype with a small amount of white adipose tissue. In the present study, we examined whether PRIP is involved in energy metabolism, which could explain the lean phenotype, using high-fat diet (HFD)-fed mice. Prip-KO mice showed resistance to HFD-induced obesity, resulting in protection from glucose metabolism dysfunction and insulin resistance. Energy expenditure and body temperature at night were significantly higher in Prip-KO mice than in wild-type mice. Gene and protein expression of uncoupling protein 1 (UCP1), a thermogenic protein, was up-regulated in Prip-KO brown adipocytes in thermoneutral or cold environments. These phenotypes were caused by the promotion of lipolysis in Prip-KO brown adipocytes, which is triggered by up-regulation of phosphorylation of the lipolysis-related proteins hormone-sensitive lipase and perilipin, followed by activation of UCP1 and/or up-regulation of thermogenesis-related genes (e.g. peroxisome proliferator-activated receptor-γ coactivator-1α). The results indicate that PRIP negatively regulates UCP1-mediated thermogenesis in brown adipocytes.
Collapse
Affiliation(s)
- Kana Oue
- From the Departments of Cellular and Molecular Pharmacology, Dental Anesthesiology, and
| | - Jun Zhang
- From the Departments of Cellular and Molecular Pharmacology
| | | | - Satoshi Asano
- From the Departments of Cellular and Molecular Pharmacology
| | | | | | - Hisako Furusho
- Oral and Maxillofacial Pathobiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553 and
| | - Takashi Takata
- Oral and Maxillofacial Pathobiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553 and
| | | | - Masato Hirata
- the Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | | |
Collapse
|
7
|
Harada-Hada K, Harada K, Kato F, Hisatsune J, Tanida I, Ogawa M, Asano S, Sugai M, Hirata M, Kanematsu T. Phospholipase C-related catalytically inactive protein participates in the autophagic elimination of Staphylococcus aureus infecting mouse embryonic fibroblasts. PLoS One 2014; 9:e98285. [PMID: 24865216 PMCID: PMC4035314 DOI: 10.1371/journal.pone.0098285] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Accepted: 04/29/2014] [Indexed: 01/22/2023] Open
Abstract
Autophagy is an intrinsic host defense system that recognizes and eliminates invading bacterial pathogens. We have identified microtubule-associated protein 1 light chain 3 (LC3), a hallmark of autophagy, as a binding partner of phospholipase C-related catalytically inactive protein (PRIP) that was originally identified as an inositol trisphosphate-binding protein. Here, we investigated the involvement of PRIP in the autophagic elimination of Staphylococcus aureus in infected mouse embryonic fibroblasts (MEFs). We observed significantly more LC3-positive autophagosome-like vacuoles enclosing an increased number of S. aureus cells in PRIP-deficient MEFs than control MEFs, 3 h and 4.5 h post infection, suggesting that S. aureus proliferates in LC3-positive autophagosome-like vacuoles in PRIP-deficient MEFs. We performed autophagic flux analysis using an mRFP-GFP-tagged LC3 plasmid and found that autophagosome maturation is significantly inhibited in PRIP-deficient MEFs. Furthermore, acidification of autophagosomes was significantly inhibited in PRIP-deficient MEFs compared to the wild-type MEFs, as determined by LysoTracker staining and time-lapse image analysis performed using mRFP-GFP-tagged LC3. Taken together, our data show that PRIP is required for the fusion of S. aureus-containing autophagosome-like vacuoles with lysosomes, indicating that PRIP is a novel modulator in the regulation of the innate immune system in non-professional phagocytic host cells.
Collapse
Affiliation(s)
- Kae Harada-Hada
- Department of Cellular and Molecular Pharmacology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kana Harada
- Department of Cellular and Molecular Pharmacology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Fuminori Kato
- Department of Bacteriology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Junzo Hisatsune
- Department of Bacteriology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Isei Tanida
- Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan
| | - Michinaga Ogawa
- Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan
| | - Satoshi Asano
- Department of Cellular and Molecular Pharmacology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Motoyuki Sugai
- Department of Bacteriology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Masato Hirata
- Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - Takashi Kanematsu
- Department of Cellular and Molecular Pharmacology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- * E-mail:
| |
Collapse
|